91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

语言

切换导航

我的购物车

搜索

语言

Darovasertib

PKC 抑制剂

规格或纯度: 99%

CAS编号: 1874276-76-2
分子式: C₂₂H₂₃F₃N₈O
分子量: 472.47
PubChem编号: 118873253

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货	价格	数量
D413600-2mg	2mg	现货
D413600-5mg	5mg	现货
D413600-10mg	10mg	现货
D413600-25mg	25mg	现货
D413600-50mg	50mg	现货
D413600-100mg	100mg	现货

查看相关系列

protein kinase C alpha Inhibitor protein kinase C theta Inhibitor

Skip to the end of the images gallery

main product photo

Skip to the beginning of the images gallery

基本描述

规格或纯度	99%
英文名称	Darovasertib
别名	LXS-196；LXS196；IDE196
英文别名	LXS-196；LXS196；IDE196
生化机理	Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC).
储存温度	-20°C储存
运输条件	超低温冰袋运输
产品介绍	Information Darovasertib (LXS-196) Darovasertib (LXS-196, IDE-196) is a selective inhibitor of protein kinase C (PKC) . Targets PKC

产品属性

ALogP	1.6
HBD Count	3
Rotatable Bond	5

名称和标识符

IUPAC Name	3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide
INCHI	InChI=1S/C22H23F3N8O/c1-21(27)6-10-33(11-7-21)15-5-3-9-29-19(15)32-20(34)17-18(26)30-12-14(31-17)16-13(22(23,24)25)4-2-8-28-16/h2-5,8-9,12H,6-7,10-11,27H2,1H3,(H2,26,30)(H,29,32,34)
InChi Key	XXJXHXJWQSCNPX-UHFFFAOYSA-N
Canonical SMILES	CC1(CCN(CC1)C2=C(N=CC=C2)NC(=O)C3=NC(=CN=C3N)C4=C(C=CC=N4)C(F)(F)F)N
PubChem CID	118873253
分子量	472.47

数据库链接

PubChem CID	118873253
ChEMBL Ligand	CHEMBL3982723
BindingDB Ligand	251460
CAS Registry No.	1874276-76-2

化学和物理性质

溶解性	Solubility (25°C) In vitro DMSO: 60 mg/mL (126.99 mM); Ethanol: 20 mg/mL (42.33 mM); Water: Insoluble;
DMSO(mg / mL) Max Solubility	22
DMSO(mM) Max Solubility	46.5638029927826
Water(mg / mL) Max Solubility	＜1

关联配体

Ligand ID	11186
名称	darovasertib
别名	LXS-196
类别	Synthetic organic
学名	3-amino-N-[3-(4-amino-4-methylpiperidin-1-yl)pyridin-2-yl]-6-[3-(trifluoromethyl)pyridin-2-yl]pyrazine-2-carboxamide
生物活性评价	The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).
评价	Darovasertib (LXS196) is an oral protein kinase C (PKC) inhibitor that was developed by Novartis for antineoplastic potential. It is one of the chemical structures claimed in Novartis' patent WO2016020864A1 . Darovasertib is a potential first-in-class protein kinase C (PKC) inhibitor.
临床描述	This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
来源公司	IDEAYA Biosciences Novartis

相关文档

质检报告COA

请输入批号:

SDS中文版 SDS英文版

质量技术规格说明书

产品问答

产品问答

登录提交问题

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

上海阿拉丁生化科技股份有限公司

销售条款及条件 ? ? ? ? 隐私政策

? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任

沪公网安备 31012002004058号沪ICP备09093490号-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

危险品化学品经营许可证（带存储）

营业执照(三证合一)